Journal of Reproductive Immunology
Volume 85, Issue 1 , Pages 76-80 , May 2010

Mechanisms of the embryo's response to embryopathic stressors: a focus on p53

  • Arkady Torchinsky

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +972 3 6409272; fax: +972 3 6406149.
    • ,
  • Vladimir Toder

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +972 3 6409626; fax: +972 3 6406149.

Received 13 September 2009 ,Revised 8 December 2009 ,Accepted 22 January 2010.

References 

  1. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR. High-frequency developmental abnormalities in p53-deficient mice. Curr. Biol. 1995;5:931–936
  2. Aylon Y, Oren M. Living with p53, dying of p53. Cell. 2007;130:597–600
  3. Baatout S, Jacquet P, Michaux A, Buset J, Vankerkom J, Derradji H, et al. Developmental abnormalities induced by X-irradiation in p53 deficient mice. In Vivo. 2002;16:215–221
  4. Bhuller Y, Jeng W, Wells PG. Variable in vivo embryoprotective role for ataxia-telangiectasia-mutated against constitutive and phenytoin-enhanced oxidative stress in atm knockout mice. Toxicol. Sci. 2006;93:146–155
  5. Bhuller Y, Wells PG. A developmental role for ataxia-telangiectasia mutated in protecting the embryo from spontaneous and phenytoin-enhanced embryopathies in culture. Toxicol. Sci. 2006;93:156–163
  6. Canman CE, Lim DS. The role of ATM in DNA damage responses and cancer. Oncogene. 1998;17:3301–3308
  7. Danilova N, Sakamoto KM, Lin S. Role of p53 family in birth defects: lessons from zebrafish. Birth Defects Res. C: Embryo Today. 2008;84:215–227
  8. Derradji H, Bekaert S, De Meyer T, Jacquet P, Abou-El-Ardat K, Ghardi M, et al. Ionizing radiation-induced gene modulations, cytokine content changes and telomere shortening in mouse fetuses exhibiting forelimb defects. Dev. Biol. 2008;322:302–313
  9. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356:215–221
  10. Doseff AI. Apoptosis: the sculptor of development. Stem Cells Dev. 2004;13:473–483
  11. Edwards MJ. Hyperthermia as a teratogen: a review of experimental studies and their clinical significance. Teratog. Carcinog. Mutagen. 1986;6:563–582
  12. Fraser FC. The multifactorial/threshold concept—uses and misuses. Teratology. 1976;14:267–280
  13. Genini D, Adachi S, Chao Q, Rose DW, Carrera CJ, Cottam HB, et al. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood. 2000;96:3537–3543
  14. Gottlieb E, Haffner R, King A, Asher G, Gruss P, Lonai P, et al. Transgenic mouse model for studying the transcriptional activity of the p53 protein: age- and tissue-dependent changes in radiation-induced activation during embryogenesis. EMBO J. 1997;16:1381–1390
  15. Green DR. Apoptotic pathways: the roads to ruin. Cell. 1998;94:695–698
  16. Horn HF, Vousden KH. Coping with stress: multiple ways to activate p53. Oncogene. 2007;26:1306–1316
  17. Hosako H, Francisco LE, Martin GS, Mirkes PE. The roles of p53 and p21 in normal development and hyperthermia-induced malformations. Birth Defects Res. B: Dev. Reprod. Toxicol. 2009;86:40–47
  18. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, et al. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 1994;4:1–7
  19. Kato F, Ootsuyama A, Nomoto S, Kondo S, Norimura T. Threshold effect for teratogenic risk of radiation depends on dose-rate and p53-dependent apoptosis. Int. J. Radiat. Biol. 2001;77:13–19
  20. Kennedy JC, Memet S, Wells PG. Antisense evidence for nuclear factor-kappaB-dependent embryopathies initiated by phenytoin-enhanced oxidative stress. Mol. Pharmacol. 2004;66:404–412
  21. Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358:15–16
  22. Minelli A, Bellezza I, Tucci A, Rambotti MG, Conte C, Culig Z. Differential involvement of reactive oxygen species and nucleoside transporters in cytotoxicity induced by two adenosine analogues in human prostate cancer cells. Prostate. 2009;69:538–547
  23. Mirkes PE. Cyclophosphamide teratogenesis: a review. Teratog. Carcinog. Mutagen. 1985;5:75–88
  24. Mirkes PE. Cell death in normal and abnormal development. Congenit. Anom. (Kyoto). 2008;48:7–17
  25. Moallem SA, Hales BF. The role of p53 and cell death by apoptosis and necrosis in 4-hydroperoxycyclophosphamide-induced limb malformations. Development. 1998;125:3225–3234
  26. Molotski N, Savion S, Gerchikov N, Fein A, Toder V, Torchinsky A. Teratogen-induced distortions in the classical NF-kappaB activation pathway: correlation with the ability of embryos to survive teratogenic stress. Toxicol. Appl. Pharmacol. 2008;229:197–205
  27. Narai S, Kodama Y, Maeda Y, Yokoyama M, Takagi R, Kominami R. Trp53 affects the developmental anomaly of clefts of the palate in irradiated mouse embryos but not clefts of the lip with or without the palate. Radiat. Res. 2006;166:877–882
  28. Nicol CJ, Harrison ML, Laposa RR, Gimelshtein IL, Wells PG. A teratologic suppressor role for p53 in benzo[a]pyrene-treated transgenic p53-deficient mice. Nat. Genet. 1995;10:181–187
  29. Norimura T, Nomoto S, Katsuki M, Gondo Y, Kondo S. p53-dependent apoptosis suppresses radiation-induced teratogenesis. Nat. Med. 1996;2:577–580
  30. Pekar O, Molotski N, Savion S, Fein A, Toder V, Torchinsky A. p53 regulates cyclophosphamide teratogenesis by controlling caspases 3, 8, 9 activation and NF-kappaB DNA binding. Reproduction. 2007;134:379–388
  31. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat. Med. 2005;11:1306–1313
  32. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T. A subset of p53-deficient embryos exhibit exencephaly. Nat. Genet. 1995;10:175–180
  33. Schmid P, Lorenz A, Hameister H, Montenarh M. Expression of p53 during mouse embryogenesis. Development. 1991;113:857–865
  34. Torchinsky A, Fein A, Toder V. Teratogen-induced apoptotic cell death: does the apoptotic machinery act as a protector of embryos exposed to teratogens?. Birth Defects Res. C: Embryo Today. 2005;75:353–361
  35. Torchinsky A, Lishanski L, Wolstein O, Shepshelovich J, Orenstein H, Savion S, et al. NF-kappa B DNA-binding activity in embryos responding to a teratogen, cyclophosphamide. BMC Dev. Biol. 2002;2:2
  36. Torchinsky A, Toder V. To die or not to die: the function of the transcription factor NF-kappaB in embryos exposed to stress. Am. J. Reprod. Immunol. 2004;51:138–143
  37. Wang B. Involvement of p53-dependent apoptosis in radiation teratogenesis and in the radioadaptive response in the late organogenesis of mice. J. Radiat. Res. (Tokyo). 2001;42:1–10
  38. Wells PG, McCallum GP, Chen CS, Henderson JT, Lee CJ, Perstin J, et al. Oxidative stress in developmental origins of disease: teratogenesis, neurodevelopmental deficits, and cancer. Toxicol. Sci. 2009;108:4–18
  39. Wubah JA, Ibrahim MM, Gao X, Nguyen D, Pisano MM, Knudsen TB. Teratogen-induced eye defects mediated by p53-dependent apoptosis. Curr. Biol. 1996;6:60–69

PII: S0165-0378(10)00037-9

doi: 10.1016/j.jri.2010.01.003

Journal of Reproductive Immunology
Volume 85, Issue 1 , Pages 76-80 , May 2010

Article Tools

* Image Usage & Resolution